Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-CAR-ipsNKT cells
- Development stage
- Preclinical
- Lead developer
- BrightPath Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
HER2-CAR-ipsNKT cells is an investigational, off-the-shelf, allogeneic chimeric antigen receptor (CAR) invariant natural killer T (iNKT) cell therapy derived from induced pluripotent stem cells (iPSCs). Developed by BrightPath Biotherapeutics in collaboration with RIKEN and Chiba University, the therapy is engineered to express a CAR targeting human epidermal growth factor receptor 2 (HER2). By utilizing iPSC-derived iNKT cells as a cellular backbone, the therapy aims to overcome manufacturing limitations associated with the low abundance of native iNKT cells in peripheral blood. HER2-CAR-ipsNKT cells exert direct cytotoxicity against HER2-positive tumor cells and promote a robust, indirect anti-tumor immune response by releasing cytokines (such as IFN-gamma, TNF-alpha, and IL-4), inducing dendritic cell maturation, promoting M1 macrophage polarization, and activating host endogenous tumor-specific cytotoxic T lymphocytes (CTLs) within the tumor microenvironment.
- Other names
- HER2 CAR-iNKT cellsHER-2 CAR-iNKT cellsHER 2 CAR-iNKT cellsHER2 CAR-iPSNKT cellsHER-2 CAR-iPSNKT cellsHER 2 CAR-iPSNKT cellsHER2-targeting CAR-ipsNKT cellsHER-2-targeting CAR-ipsNKT cellsHER 2-targeting CAR-ipsNKT cellsiPSC-derived HER2 CAR-iNKT cellsiPSC-derived HER2 CAR-ipsNKT cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-CAR-ipsNKT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-CAR-ipsNKT cells.